Ignite Creation Date:
2024-05-06 @ 7:13 PM
Last Modification Date:
2024-10-26 @ 3:02 PM
Study NCT ID:
NCT05937295
Status:
RECRUITING
Last Update Posted:
2023-09-29
First Post:
2023-05-09
Brief Title:
FusionVAC22_01 Fusion Transcript-based Peptide Vaccine Combined With Immune Checkpoint Inhibition
Sponsor:
University Hospital Tuebingen
Organization:
University Hospital Tuebingen
Study Overview
Official Title:
FusionVAC22_01 DNAJB1-PRKACA Fusion Transcript-based Peptide Vaccine Combined With Immune Checkpoint Inhibition for Fibrolamellar Hepatocellular Carcinoma and Other Tumor Entities Carrying the Oncogenic Driver Fusion
Status:
RECRUITING
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FusionVAC22
Brief Summary:
The aim of this clinical trial is to evaluate the immunogenicity along with safety and toxicity as well as first efficacy of a DNAJB1-PRKACA fusion transcript-based peptide vaccine Fusion-VAC-XS15 in combination with anti-programmed cell death-ligand 1 immune checkpoint inhibition ICI by Atezolizumab TecentriqTM in patients with Fibrolamellar hepatocellular carcinoma FL-HCC or other cancer entities carrying the DNAJB1-PRKACA fusion transcript
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2022-502869-17-01 | OTHER | Eu-CT Number | None |